Drug Profile

Sialidase 1 targeting therapeutics - Collaborations Pharmaceuticals

Latest Information Update: 01 Mar 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Collaborations Pharmaceuticals
Class Small molecules
Mechanism of Action Neuraminidase modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Lysosomal storage diseases

Most Recent Events

21 Feb 2022 Sialidosis therapeutics - Collaborations Pharmaceuticals is available for licensing as of 07 Feb 2022. https://www.collaborationspharma.com/how-we-collaborate
07 Feb 2022 Collaborations Pharmaceuticals has patent pending for sialidosis before February 2022 (Collaborations Pharmaceuticals pipeline, February 2022)
20 Jun 2021 Preclinical trials in Lysosomal storage diseases in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com